| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912765 | RVL PHARMS | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(7 years from now) | |
| US8357714 | RVL PHARMS | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(7 years from now) | |
| US9867808 | RVL PHARMS | Compositions and methods for non-surgical treatment of Ptosis |
Aug, 2031
(7 years from now) | |
| US10814001 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11311515 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11324722 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US11541036 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US10898573 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US10799481 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US11103482 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11701343 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US10940138 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
Upneeq is owned by Rvl Pharms.
Upneeq contains Oxymetazoline Hydrochloride.
Upneeq has a total of 12 drug patents out of which 0 drug patents have expired.
Upneeq was authorised for market use on 08 July, 2020.
Upneeq is available in solution/drops;ophthalmic dosage forms.
Upneeq can be used as method of treating blepharoptosis.
The generics of Upneeq are possible to be released after 16 December, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 08, 2023 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 July, 2020
Treatment: Method of treating blepharoptosis
Dosage: SOLUTION/DROPS;OPHTHALMIC
UPNEEQ family patents
